



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Siwanon Jirawatnotai
✉ Siwanon.jirawatnotai@mahidol.ac.th

SPECIALTY SECTION
This article was submitted to
Cancer Molecular Targets
and Therapeutics,
a section of the journal
Frontiers in Oncology

RECEIVED 15 December 2022

ACCEPTED 19 December 2022

PUBLISHED 06 January 2023

CITATION
Prasopporn S, Suppramote O,
Ponvilawan B, Jamyuang C,
Chanthercrob J, Chaiboonchoe A,
More-Krong P, Kongsri K,
Suntiparpluacha M, Chanwat R,
Korphaisarn K, Okada S,
Sampattavanich S and Jirawatnotai S
(2023) Corrigendum: Combining the
SMAC mimetic LCL161 with
Gemcitabine plus Cisplatin therapy
inhibits and prevents the emergence
of multidrug resistance in
cholangiocarcinoma.
Front. Oncol. 12:1124912.
doi: 10.3389/fonc.2022.1124912

COPYRIGHT

© 2023 Prasopporn, Suppramote,
Ponvilawan, Jamyuang, Chanthercrob,
Chaiboonchoe, More-Krong, Kongsri,
Suntiparpluacha, Chanwat, Korphaisarn,
Okada, Sampattavanich and
Jirawatnotai. This is an open-access
article distributed under the terms of
the [Creative Commons Attribution
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution
or reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s)
are credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.

Corrigendum: Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma

Sunisa Prasopporn^{1,2}, Orawan Suppramote^{2,3},
Ben Ponvilawan², Chanette Jamyuang²,
Jantappapa Chanthercrob¹, Amphun Chaiboonchoe¹,
Pimkanya More-Krong¹, Kamonchanok Kongsri¹,
Monthira Suntiparpluacha¹, Rawisak Chanwat⁴,
Krittiya Korphaisarn⁵, Seiji Okada⁶,
Somponnat Sampattavanich^{1,2} and Siwanon Jirawatnotai^{1,2*}

¹Siriraj Center of Research Excellence for Precision Medicine and Systems Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, ²Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, ³Princess Srisavangavadhana College of Medicine, Chulabhorn Royal Academy, Bangkok, Thailand, ⁴HepatoPancreato-Biliary Surgery Unit, Department of Surgical Oncology, National Cancer Institute, Bangkok, Thailand, ⁵Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, ⁶Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan

KEYWORDS

SMAC mimetics, LCL161, Gemcitabine plus Cisplatin therapy, multidrug resistance, cholangiocarcinoma, acquired vulnerability

A Corrigendum on

Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma

by Prasopporn S, Suppramote O, Ponvilawan B, Jamyuang C, Chanthercrob J, Chaiboonchoe A, More-Krong P, Kongsri K, Suntiparpluacha M, Chanwat R, Korphaisarn K, Okada S, Sampattavanich S and Jirawatnotai S (2022) *Front. Oncol.* 12:1021632. doi: 10.3389/fonc.2022.1021632

In the published article, there was an error in the Funding statement. There was one missing funding agency from our manuscript. The correct Funding statement appears below.

Funding

This study was funded by grants from the National Science and Technology Development Agency (NSTDA) of Thailand, the Japan Science and Technology Agency, and the National Institute of Allergy and Infectious Diseases of the United States as part of the e-ASIA Joint Research Program (e-ASIA JRP); the NSTDA (P-15-50208), the National Research Council of Thailand (NRCT) R016441034, the Advanced Research in Pharmacology Fund, Siriraj Foundation (D003421), and by Mahidol University (Basic Research Fund, and the grant of fiscal year 2022).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.